Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, D. Caillot et al.|Blood|2025Cited by 34
First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.Aurore Perrot, Cyrille Touzeau, Cyrille Hulin et al.|Blood|2025Cited by 0